Alpha Tau Medical Ltd.
DRTSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the. The company carries a $1.22B market cap, placing it firmly in the small-cap category. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Market Cap
$1.22B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-24.62
EPS (TTM)
$-1.04
EPS (Fwd)
$-0.53
ROE
-141.7%
ROA
-25.7%
Cash
$100.6M
Total Debt
$15.2M
Free CF
-$20.3M
52W Change
211.1%
Annual Financials
Cash vs Debt
Where DRTS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DRTS finished 11.09% above its 150-day moving average ($11.36) and 22.64% above its 200-day moving average ($10.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DRTS overbought or oversold?
At the October 20, 2026 close, DRTS's RSI(14) was 23.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $100.6M in cash and $15.2M in debt, DRTS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$20.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -141.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DRTS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.